Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration

Inclusion Criteria: * Patients older than 55 years with treatment naïve, active subfoveal NVAMD demonstrating macular fluid on optical coherence tomography (OCT) and leakage on fluorescein angiography (FA). * Only one eye for each patient demonstrating a pre-treatment acuity of 20/25 - 20/320 is eligible * Patients cannot have concurrent progressive retinal disease in the study eye. * Willing and able to comply with clinic visits and study-related procedures * Provide signed informed consent Exclusion Criteria: * Prior treatment for NVAMD in the study eye, * Prior experimental treatment of NVAMD in either eye * Prior treatment with systemic anti-VEGF (vascular endothelial growth factor) agents * Prior treatment with verteporfin, plaque brachytherapy, or external-beam radiation therapy, or transpupillary thermotherapy in the study eye * Previous subfoveal focal laser photocoagulation involving the foveal center in the study eye * History of vitreo surgical intervention in the study eye. Cataract surgery is permitted. * Concurrent eye disease in the study eye that could compromise visual acuity (e.g. diabetic retinopathy, advanced glaucoma) * Any concurrent intraocular condition in the study eye (e.g. diabetic retinopathy or glaucoma) that, in the opinion of the investigator, could either * require medical or surgical intervention during the 52 weeks study period to prevent or treat visual loss that might result from that condition, or * allowed to progress untreated, could likely contribute to loss of at least 2 Snellen equivalent lines of best corrected visual acuity over the 52 weeks study period * Active intraocular inflammation (grade trace or above) in the study eye, or history of idiopathic or autoimmune-associated uveitis in either eye * Current vitreous hemorrhage in the study eye * History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye * Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye * Aphakia, Anterior Chamber Intraocular Lens (ACIOL), or unstable Posterior Chamber Intraocular Lens (PCIOL). * Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmHg despite treatment with anti-glaucoma medication) * Pregnant or breast-feeding women * Sexually active men\* or women of childbearing potential\*\* who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device \[IUD\]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly)